The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...
The FDA approved a taurolidine and heparin (DefenCath) catheter lock solution for reducing the risk of bloodstream infections in patients on dialysis. Approved under a special limited agency pathway, ...
Totally subcutaneous vascular access is theoretically attractive in that transcutaneous egress of a prosthetic device is avoided. Assuming appropriate aseptic technique during access, this should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results